Tel: +44 (0) 20 7597 5970 Daniel Adams / Patrick Robb / Gary Clarence AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand
®, RESORBA
®, and LiquiBandFix8
®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal
® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.
Chippenham, UK - 30 December 2020: Vectura Group plc (LSE: VEC) ( Vectura , the Group , or the Company ), an industry-leading specialist inhalation CDMO, is pleased to announce the appointments of Jeanne Hecht and Jeanne Thoma as Independent Non-Executive Directors of the Company with effect from 31
st December 2020.
Jeanne Hecht was most recently CEO of Ora, Inc. ( Ora ) a full-service pre-clinical and clinical ophthalmic drug and device development firm. Previously she served as Chief Operating Officer and was a Board Director of Median Technologies, a clinical services imaging business. Prior to this Jeanne had a substantial career with Quintiles (later IQVIA), the world s largest contract development services company, where she led global sales and strategic accounts.
Oasmia Pharmaceutical : Secures Valuable IP Rights in Australia and Brazil marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Appointment of Professor Akiko Iwasaki to Scientific Advisory Board
December 18, 2020 02:00 ET | Source: 4Bio Capital 4Bio Capital
Professor of Molecular, Cellular and Developmental Biology and Immunology at Yale University
Principal investigator at the Howard Hughes Medical Institute
Brings extensive experience in Immunology within the field of infectious diseases, most recently in COVID-19
18 December 2020
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Akiko Iwasaki to its Scientific Advisory Board (SAB).
Professor Iwasaki has made significant contributions towards understanding innate and adaptive immunity. Throughout her research career she has made major breakthroughs including the demonstration of tissue-specific properties of dendritic cells, how DNA vaccines elicit an immune response, and bei
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amryt Granted Orphan Drug Designation by the FDA for AP103
Amryt Pharma plcDecember 23, 2020 GMT
Amryt Granted Orphan Drug Designation by the FDA for AP103
DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for AP103 for the treatment of Dystrophic Epidermolysis Bullosa (“DEB”). AP103 is based on Amryt’s gene-therapy platform technology and offers a potential treatment for patients with DEB, a subset of EB.